An HLA antibody test checks blood for antibodies against human leukocyte antigen markers. These antibodies can develop after pregnancy, blood transfusion, or a previous transplant and may make it harder to find a compatible organ or stem-cell donor. Results may be reported as an antibody screen, individual HLA specificities, panel-reactive antibody, or calculated panel-reactive antibody. A high PRA or cPRA does not mean a person has an autoimmune disease, and it does not prove that a particular donor is incompatible. It means the person is sensitized to a larger share of the donor population. Compatibility depends on whether an antibody targets an HLA marker carried by the actual donor, whether the crossmatch is positive, and how the transplant program interprets antibody strength and history. Testing is repeated because antibody patterns can change. The most useful result is a complete profile reviewed by a histocompatibility laboratory and transplant team, not a single percentage or MFI number.
- HLA antibody testing identifies immune sensitization that may affect donor selection and rejection risk.
- PRA or cPRA estimates how difficult it may be to find a compatible donor; it is not a rejection diagnosis.
- Donor-specific antibody is present only when the donor carries the HLA target recognized by the antibody.
- MFI is a semi-quantitative assay signal, not a universal antibody concentration or fixed risk cutoff.
- A recent transfusion, pregnancy, or transplant can change results and may require repeat testing.
Table of Contents
- What the HLA Antibody Test Measures
- Why and When Testing Is Ordered
- PRA, cPRA, and Sensitization Levels
- How HLA Antibody Testing Works
- Understanding Positive and Negative Results
- How Results Affect Donor Compatibility
- Limitations, False Signals, and Changing Results
- Next Steps After an HLA Antibody Result
What the HLA Antibody Test Measures
HLA proteins are inherited cell-surface markers that help the immune system recognize the body’s own tissues. The main transplant-related HLA groups include class I molecules—HLA-A, HLA-B, and HLA-C—and class II molecules—HLA-DR, HLA-DQ, and HLA-DP.
People normally tolerate their own HLA. Exposure to another person’s cells can stimulate antibodies against HLA structures that the exposed person does not carry. This process is called alloimmunization or sensitization.
The most common sensitizing exposures are:
- Pregnancy, including delivery and miscarriage
- Red blood cell or platelet transfusion, because blood products may contain leukocytes or HLA-bearing platelets
- A previous organ or tissue transplant
- A previous allogeneic stem-cell transplant or cellular product
The test measures anti-HLA antibodies in serum. Depending on the method, it may answer one or more questions:
- Are anti-HLA antibodies present at all?
- Are they directed against class I, class II, or both?
- Which specific HLA antigens or alleles do they recognize?
- How broad is the antibody response across the donor population?
- Does the pattern include an HLA marker carried by a proposed donor?
A broad antibody screen is different from a donor-specific antibody test. DSA status can only be assigned after the recipient’s antibody specificities are compared with the donor’s HLA type.
HLA antibodies are also different from autoantibodies such as antinuclear antibody. They recognize inherited HLA differences between people, not necessarily the person’s own tissues. A positive HLA antibody test therefore does not by itself indicate lupus, rheumatoid arthritis, or another autoimmune disease.
Some laboratories test non-HLA antibodies, but those are separate assays. The standard PRA, cPRA, and single-antigen bead reports focus mainly on HLA.
Why and When Testing Is Ordered
HLA antibody testing is central to transplant evaluation and follow-up. It helps the team avoid donors likely to trigger a strong immune response while preserving as many safe donor options as possible.
Before an organ transplant
Candidates are tested during the initial evaluation and periodically while waiting. The laboratory identifies unacceptable HLA antigens—targets that the program believes create excessive risk if present in a donor. These designations can be used in computerized organ allocation and virtual crossmatching.
Testing may be repeated monthly, quarterly, or on another center-specific schedule. A new sample is often required after a sensitizing event. A serum specimen drawn before a transfusion or pregnancy may no longer represent current risk.
For a living donor, the result helps determine whether direct donation appears feasible. If the recipient has antibodies against that donor, options may include another donor, kidney paired donation, or a higher-risk protocol with additional assessment.
Before stem-cell transplantation
In HLA-mismatched hematopoietic cell transplantation, recipient antibodies against donor HLA can increase the risk of delayed engraftment or graft failure. Testing is particularly relevant for haploidentical donors, cord blood, and mismatched unrelated donors. The team may prefer a donor whose mismatched HLA is not targeted by recipient antibody.
After transplantation
Post-transplant testing may be routine or prompted by graft dysfunction. The purpose is usually to detect donor-specific antibodies, including antibodies that develop for the first time after transplant. These de novo antibodies can be associated with antibody-mediated rejection, but antibody findings must be interpreted with organ function and, when appropriate, biopsy results.
After a sensitizing exposure
Antibodies do not always appear immediately. The immune response may evolve over days or weeks after pregnancy, transfusion, or transplantation. A center may collect a new sample after the exposure and again later, depending on urgency and protocol.
Tell the transplant team about every transfusion, even one given at another hospital. Platelet transfusions are particularly relevant because platelets express HLA class I. Leukoreduction reduces exposure but does not eliminate sensitization risk.
PRA, cPRA, and Sensitization Levels
Panel-reactive antibody is a way to describe the breadth of sensitization. The terminology has evolved, and reports may use PRA and cPRA differently.
Traditional PRA
Traditional PRA measured how often a recipient’s serum reacted with a panel of cells chosen to represent a donor population. If serum reacted with 60 of 100 panel samples, the PRA was approximately 60%. The result depended heavily on how well the panel represented the relevant population.
Modern laboratories still use “PRA” conversationally, but many allocation systems rely on calculated PRA.
Calculated PRA
cPRA is calculated from the HLA antigens listed as unacceptable and their frequencies among donors in a defined population. A cPRA of 80% means that approximately 80% of donors in that reference population would be expected to carry one or more unacceptable HLA antigens. It does not mean the person has an 80% chance of rejecting every transplant.
A simplified interpretation is:
| cPRA range | General meaning | Practical effect |
|---|---|---|
| 0% | No unacceptable antigens entered for the calculation | Broadest expected donor access, though crossmatch and other factors still matter |
| 1%–19% | Low sensitization | Most donors remain potentially compatible |
| 20%–79% | Moderate sensitization | Donor options are increasingly restricted |
| 80%–97% | High sensitization | Compatible offers may be uncommon; allocation priority may apply |
| 98%–100% | Very high sensitization | Matching can be extremely difficult, especially at 99.9% or above |
These categories are illustrative, not universal medical cutoffs. Allocation rules differ by country and organ. Two people with the same rounded cPRA can have very different matching prospects because their antibody targets differ in frequency and combination.
A reported cPRA of 100% may conceal important decimals. A person at 99.50% has more potential compatible donors than a person at 99.99%, even though both may display as 100% in a simplified report. Programs may use more precise values for allocation.
cPRA can rise when the laboratory identifies new antibodies or lowers the threshold for listing an HLA antigen as unacceptable. It can fall when an antigen is removed after expert review. The percentage is therefore partly a product of clinical policy and assay interpretation, not only biology.
How HLA Antibody Testing Works
The test uses a blood sample. Fasting is not needed. Serum is separated and exposed to HLA targets in the laboratory.
Screening beads
A screening assay uses beads coated with mixtures of HLA proteins. It reports whether class I or class II antibody is likely present. Screening is efficient but does not identify every specificity.
Phenotype or panel beads
These beads carry combinations of HLA proteins resembling individual cells. They can help estimate antibody breadth and pattern.
Single-antigen bead assay
Single-antigen beads are the most detailed common method. Each bead is coated mainly with one HLA antigen or allele. Antibody binding produces fluorescence, reported as mean fluorescence intensity, or MFI. The pattern helps assign specific targets such as HLA-B8, HLA-DR7, or HLA-DQ6.
MFI is semi-quantitative. It is not a direct antibody concentration and should not be compared to a medication level. The relationship between MFI and actual antibody amount is nonlinear, and values can vary by laboratory, reagent lot, sample treatment, and antigen.
Laboratories interpret more than the raw number. They examine background, bead patterns, shared epitopes, historical results, serum dilutions, and crossmatch correlation. An isolated weak bead may be less convincing than a coherent pattern across structurally related HLA targets.
Complement-binding and dilution tests
Some centers use C1q or C3d assays to evaluate complement activation, or titration to see how long reactivity persists as serum is diluted. These tests may refine risk but do not replace the core specificity analysis.
Cell-based crossmatch
A cell-based crossmatch mixes recipient serum with donor lymphocytes. Flow cytometry detects antibody binding, while complement-dependent cytotoxicity looks for cell killing. A virtual crossmatch instead compares the antibody profile with donor HLA typing electronically.
The laboratory may store several serum samples. Historical antibodies remain relevant even if the newest sample is negative, because immune memory can produce a rapid rebound after re-exposure.
Understanding Positive and Negative Results
Negative HLA antibody screen
A negative screen means no antibody was detected above the assay threshold in that sample. It usually corresponds to low sensitization and a cPRA near zero, but it does not guarantee a negative crossmatch or successful transplant.
Possible reasons for an apparently negative result include antibody below detection, a target not well represented on the assay, technical interference, or use of an old sample collected before a recent immune exposure. Non-HLA antibodies can also cause some crossmatch reactions.
Positive screen with identified specificities
A positive screen means anti-HLA antibody is present. The detailed report should state class I, class II, or both and list the likely specificities. The result becomes clinically meaningful when the team determines which targets should be considered unacceptable and whether any are donor-specific.
A positive test may remain stable for years or change over time. Some antibodies weaken until they fall below reporting thresholds, yet the historical record remains important.
Low, moderate, or strong MFI
Laboratories may group MFI into descriptive bands, but there is no universal boundary. A center might investigate an antibody near 1,000 MFI, while another uses a different threshold. The transplant type, HLA target, dilution behavior, crossmatch, and historical peak all influence interpretation.
High MFI generally increases concern, but a strong antibody can produce an unexpectedly low raw result because of the prozone effect. Dilution or chemical treatment may uncover the true reactivity. Conversely, antibody against denatured HLA on a bead may generate a high signal without binding well to living donor cells.
Class I versus class II antibodies
Class I antibodies target HLA-A, HLA-B, or HLA-C. They may produce T-cell and B-cell crossmatch reactivity. Class II antibodies target HLA-DR, HLA-DQ, or HLA-DP and usually affect the B-cell crossmatch more strongly because resting T cells do not normally express class II HLA.
HLA-DQ antibodies are common after kidney transplantation and can be clinically important. HLA-DP and HLA-C findings also matter, especially when donor typing at those loci is available. They should not be dismissed merely because older matching systems focused mainly on A, B, and DR.
Historical versus current antibody
A historical antibody was detected previously but is weak or absent now. It may still lead a center to avoid that donor antigen. A current-negative result does not erase memory B cells or long-lived immune sensitization.
The report should be interpreted as a timeline. Record the date, assay, specificity, peak signal, treatments, and sensitizing events rather than focusing only on the latest page.
How Results Affect Donor Compatibility
The antibody profile narrows the donor pool by identifying HLA targets that may be unsafe. It does not rank donors by overall quality and does not replace HLA matching, blood-group compatibility, organ size, infection screening, or medical assessment.
A proposed donor is immunologically concerning when the donor carries an HLA target recognized by the recipient’s antibody. That antibody is then donor-specific. Risk is higher when the antibody is strong, persistent, complement-binding, present at high titer, or associated with a positive flow or cytotoxic crossmatch.
For deceased-donor allocation, unacceptable antigens can be entered into a registry. Donors carrying those HLA markers are filtered out before an offer reaches the candidate. This virtual approach reduces avoidable positive crossmatches and allows highly sensitized candidates to be matched across larger regions.
Overly broad unacceptable-antigen listing can unnecessarily block safe donors. Under-listing can expose a patient to high-risk offers. Histocompatibility specialists balance assay sensitivity with evidence that the antibody binds native HLA and predicts clinical risk.
For living-donor kidney transplant, an incompatible antibody profile does not always end the process. Kidney paired donation can exchange donors among pairs to find immunologically safer matches. Some centers offer desensitization for selected patients, using combinations that reduce or neutralize antibodies. Desensitization carries infection, rejection, cost, and rebound risks and is not appropriate for every case.
For hematopoietic cell transplantation, the team may select a donor whose mismatched HLA targets are not recognized. If no alternative exists, DSA treatment and close engraftment monitoring may be considered.
A high cPRA affects access more than it defines the risk of a specific accepted donor. A person with cPRA 99% can have an excellent outcome with a donor who lacks all unacceptable targets and has a negative crossmatch.
Limitations, False Signals, and Changing Results
HLA antibody assays are highly sensitive, but their manufactured HLA proteins do not perfectly reproduce HLA on living cells. Interpretation requires technical expertise.
Common limitations include:
- Denatured antigen exposing artificial antibody targets
- Prozone or complement interference producing falsely low MFI
- Nonspecific background binding
- Shared epitopes causing several beads to react
- Incomplete donor HLA typing
- Lot-to-lot or run-to-run variation
- Different laboratory thresholds and population-frequency calculations
- Treatment effects from plasma exchange, intravenous immunoglobulin, rituximab, or other therapies
- An outdated serum sample after a sensitizing event
MFI changes of a few hundred units may be noise, especially near the cutoff. Larger trends are more persuasive when samples are tested with the same method and the pattern is reproduced.
Intravenous immunoglobulin can produce complex assay effects. Plasma exchange may temporarily lower circulating antibody without eliminating the cells that produce it. Anti-CD38 and other therapies may interfere with some laboratory methods. Treatment dates should accompany the specimen.
cPRA depends on the donor population used for calculation. A value generated in one country or allocation system may not be identical to a value calculated elsewhere. HLA frequencies also differ by ancestry, so a numerical cPRA cannot fully describe equity or individual access.
A positive antibody result does not diagnose rejection after transplant. Infection, medication toxicity, vascular problems, recurrent disease, and T-cell-mediated rejection can also impair graft function. DSA, organ tests, imaging, and biopsy may all be needed.
Next Steps After an HLA Antibody Result
Ask for an explanation that connects the antibody report to the transplant plan. Useful questions include:
- Is the screen positive for class I, class II, or both?
- Which exact HLA specificities were identified?
- What are the current and historical peak results?
- Which antigens are listed as unacceptable, and why?
- What is the cPRA using the current allocation system?
- Was serum dilution or interference testing needed?
- Does a proposed donor carry any of these targets?
- What do the virtual and physical crossmatches show?
- When should testing be repeated?
Report every new transfusion, pregnancy, miscarriage, transplant, or major immune treatment. Keep the transplant center’s contact information available when receiving care elsewhere so blood-product decisions and sample timing can be coordinated.
For a low or zero cPRA, continue scheduled testing. Antibody status can change, and a current sample is still needed for donor assessment.
For moderate or high cPRA, ask whether broader allocation, acceptable-mismatch programs, paired donation, or multiple listing is available. The best option depends on organ type, location, medical urgency, and center policy.
For a newly positive result after transplant, contact the transplant team rather than adjusting immunosuppressants independently. The team may repeat testing, review adherence and drug levels, assess graft function, or perform a biopsy. Early identification of a correctable problem can protect the graft.
Keep copies of full reports, not just the percentage. The specific antibody targets and historical peaks often matter more than the headline PRA. When changing transplant centers, arrange transfer of the complete histocompatibility record and stored-serum history when possible.
HLA antibody testing works best as a dynamic safety system. Repeated samples, accurate donor typing, expert interpretation, and clear communication can convert a complicated antibody profile into a focused compatibility plan.
A single number should never be interpreted without the underlying specificity list. A high calculated PRA can result from many unacceptable antigens, while one strong antibody against a common donor antigen can also sharply restrict access. Conversely, a low cPRA does not guarantee that a particular donor is safe. The laboratory must compare the recipient antibody profile with that donor’s exact HLA type.
Trends are often more informative than isolated fluctuations. Laboratories may repeat testing after transfusion, pregnancy, transplant events, rejection, infection, or changes in immunosuppression. Small shifts in mean fluorescence intensity can reflect assay variation, dilution effects, shared epitopes, or changes in background signal. Clinicians focus on reproducible specificity, biologic plausibility, donor relevance, and the broader clinical course rather than treating every numeric change as a new immune event.
References
- Canadian Highly Sensitized Patient Program Report: A 1000 Kidney Transplants Story 2024
- European Consensus on the Management of Sensitized Kidney Transplant Recipients: A Delphi Study 2024 (Consensus)
- Advances in desensitization for human leukocyte antigen incompatible kidney transplantation 2024 (Review)
- The Clinical Utility of Post-Transplant Monitoring of Donor-Specific Antibodies in Stable Renal Transplant Recipients: A Consensus Report With Guideline Statements for Clinical Practice 2023 (Consensus)
- European Guideline for the Management of Kidney Transplant Patients With HLA Antibodies: By the European Society for Organ Transplantation Working Group 2022 (Guideline)
- Determination of unacceptable HLA antigen mismatches in kidney transplant recipients 2022 (Review)
Disclaimer
This article provides general educational information and cannot determine whether a specific donor is safe for an individual. HLA antibody, PRA, cPRA, MFI, crossmatch, and donor typing results must be interpreted by the transplant team and histocompatibility laboratory. Contact the transplant team promptly after a sensitizing event or any change in graft function.
